Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture (CAESAR)
Primary Purpose
Trauma, Inflammation, Sepsis
Status
Terminated
Phase
Phase 3
Locations
Netherlands
Study Type
Interventional
Intervention
C1-esterase inhibitor
Saline 0.9%
Sponsored by
About this trial
This is an interventional treatment trial for Trauma focused on measuring C1-esterase inhibitor, Systemic inflammation, Sepsis, Trauma, Multiple Organ Dysfunction Syndrome, Cytokines
Eligibility Criteria
Inclusion Criteria:
- Multi trauma patients
- Femur or pelvic fracture
- Injury Severity Score (ISS) ≥ 18
- Age 18-80 yrs
Exclusion Criteria:
- Congenital C1-inhibitor deficiency
- Use of immune suppressants
- Pregnancy
- Known hypersensitivity for blood products
- Fixation of femur fracture with external fixation or osteosynthesis
Sites / Locations
- University Medical Centre Utrecht
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
C1-esterase inhibitor
Saline 0.9%
Arm Description
C1-esterase inhibitor, 100 U/kg bodyweight
Saline 0.9%
Outcomes
Primary Outcome Measures
Delta Interleukine-6
Secondary Outcome Measures
Cytokines and other markers of inflammation
Neutrophil redistribution and phenotype
C1-inhibitor and complement concentration and activity
Hemodynamic response
Full Information
NCT ID
NCT01275976
First Posted
January 12, 2011
Last Updated
February 3, 2015
Sponsor
UMC Utrecht
Collaborators
Prothya Biosolutions
1. Study Identification
Unique Protocol Identification Number
NCT01275976
Brief Title
Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture
Acronym
CAESAR
Official Title
Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture
Study Type
Interventional
2. Study Status
Record Verification Date
February 2015
Overall Recruitment Status
Terminated
Why Stopped
Futility and limited feasibility
Study Start Date
April 2012 (undefined)
Primary Completion Date
February 2015 (Actual)
Study Completion Date
February 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
UMC Utrecht
Collaborators
Prothya Biosolutions
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Trauma and major operation are associated with an excessive inflammation reaction due to tissue injury. This overwhelming immune response is considered to be a major risk factor in the pathogenesis of late inflammatory complications such as acute respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS) and sepsis.
The investigators hypothesize that administration of C1-esterase inhibitor (C1-INH) will attenuate the humane inflammatory response and, thereby, reduce the risk of inflammatory complications due to surgical interventions in trauma patients with a femur or pelvic fracture
Detailed Description
Systemic inflammation in response to a femur or pelvic fracture and fixation is associated with complications, such as acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS). The injury itself, but also the additional fixation procedure give a release of pro-inflammatory cytokines, in particular interleukin (IL)-6. This results in an aggravation of the initial systemic inflammatory response, and will cause in some patients an increased risk on the development of inflammatory complications, like ARDS and MODS. Which can lead to higher morbidity, mortality and prolonged hospital stay.
Various strategies, such as damage control orthopedics, have been proposed to prevent these complications. Another strategy is to decrease the inflammatory reaction caused by the surgical procedure, and by interventions focused on inhibition of the innate inflammatory response. This will lower the risk of complications.
A promising candidate is the endogenously produced serum protein C1-esterase inhibitor (C1-INH). This protein is an acute phase protein, produced by the liver in response to inflammatory conditions. C1-INH is a major inactivator of the complement system, but important additional anti-inflammatory properties have been demonstrated. A previous study of from our laboratory showed that administration of the drug C1-INH significantly reduced the concentration of circulating pro-inflammatory cytokines such as IL-6, during human experimental endotoxemia. Treatment with C1-INH has been proven to be safe in treatment with humans, even in high dosages and in pregnant patients with C1-INH deficiency.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Trauma, Inflammation, Sepsis, Multiple Organ Dysfunction Syndrome
Keywords
C1-esterase inhibitor, Systemic inflammation, Sepsis, Trauma, Multiple Organ Dysfunction Syndrome, Cytokines
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
11 (Actual)
8. Arms, Groups, and Interventions
Arm Title
C1-esterase inhibitor
Arm Type
Active Comparator
Arm Description
C1-esterase inhibitor, 100 U/kg bodyweight
Arm Title
Saline 0.9%
Arm Type
Placebo Comparator
Arm Description
Saline 0.9%
Intervention Type
Drug
Intervention Name(s)
C1-esterase inhibitor
Other Intervention Name(s)
Cetor® (RVG 19303)
Intervention Description
C1-esterase inhibitor 200 U/kg infusion over 30 minutes, just before the start of the femur or pelvic fixation operation.
Intervention Type
Other
Intervention Name(s)
Saline 0.9%
Intervention Description
Infusion, just before the start of the femur or pelvic fixation operation
Primary Outcome Measure Information:
Title
Delta Interleukine-6
Time Frame
6 hours after C1-INH administration
Secondary Outcome Measure Information:
Title
Cytokines and other markers of inflammation
Time Frame
up to 12 days after C1-INH administration
Title
Neutrophil redistribution and phenotype
Time Frame
Up to 12 days after C1-INH administration
Title
C1-inhibitor and complement concentration and activity
Time Frame
Up to 12 days after C1-INH administration
Title
Hemodynamic response
Time Frame
Up to 12 days after C1-INH administration
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Multi trauma patients
Femur or pelvic fracture
Injury Severity Score (ISS) ≥ 18
Age 18-80 yrs
Exclusion Criteria:
Congenital C1-inhibitor deficiency
Use of immune suppressants
Pregnancy
Known hypersensitivity for blood products
Fixation of femur fracture with external fixation or osteosynthesis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Luke P Leenen, MD, PhD
Organizational Affiliation
UMC Utrecht
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Medical Centre Utrecht
City
Utrecht
ZIP/Postal Code
3508 GA
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
21988742
Citation
Heeres M, Visser T, van Wessem KJ, Koenderman AH, Strengers PF, Koenderman L, Leenen LP. The effect of C1-esterase inhibitor on systemic inflammation in trauma patients with a femur fracture - The CAESAR study: study protocol for a randomized controlled trial. Trials. 2011 Oct 11;12:223. doi: 10.1186/1745-6215-12-223.
Results Reference
derived
Learn more about this trial
Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture
We'll reach out to this number within 24 hrs